Companies / Voyager Therapeutics, Inc. / Activity
Activity — Voyager Therapeutics, Inc.
24 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | Jorgensen Nathan D. Executive | Grant | Common Stock | $0 | +32K +26.04% | 156,084 0.25% of shares | low |
| Feb 6, 2026 | Ferguson Toby Executive | Grant | Common Stock | $0 | +45K +32.39% | 183,914 0.30% of shares | low |
| Feb 6, 2026 | Carter Todd Alfred Executive | Grant | Common Stock | $0 | +33K +26.67% | 156,718 0.25% of shares | low |
| Feb 6, 2026 | Swartz Robin Executive | Grant | Common Stock | $0 | +45K +26.53% | 214,647 0.35% of shares | low |
| Feb 6, 2026 | Sandrock Alfred CEO | Grant | Common Stock | $0 | +86K +19.79% | 522,181 0.85% of shares | low |
| Feb 18, 2026 | Carter Todd Alfred Executive | Sell | Common Stock | $11.4K | -3K -2.15% | 149,892 0.24% of shares | low |
| Feb 18, 2026 | Swartz Robin Executive | Sell | Common Stock | $13.4K | -4K -1.85% | 206,196 0.33% of shares | low |
| Feb 10, 2026 | Carter Todd Alfred Executive | Sell | Common Stock | $13.6K | -4K -2.25% | 153,193 0.25% of shares | low |
| Feb 24, 2026 | Carter Todd Alfred Executive | Sell | Common Stock | $15.7K | -4K -2.78% | 145,718 0.24% of shares | low |
| Feb 10, 2026 | Swartz Robin Executive | Sell | Common Stock | $17.6K | -5K -2.13% | 210,078 0.34% of shares | low |
| Feb 24, 2026 | Jorgensen Nathan D. Executive | Sell | Common Stock | $17.6K | -5K -2.99% | 151,416 0.25% of shares | low |
| Feb 24, 2026 | Swartz Robin Executive | Sell | Common Stock | $24.3K | -6K -3.13% | 199,738 0.32% of shares | low |
| Feb 18, 2026 | Sandrock Alfred CEO | Sell | Common Stock | $40.0K | -12K -2.30% | 498,257 0.81% of shares | low |
| Feb 10, 2026 | Sandrock Alfred CEO | Sell | Common Stock | $46.1K | -12K -2.33% | 509,989 0.83% of shares | low |
| Feb 24, 2026 | Sandrock Alfred CEO | Sell | Common Stock | $53.8K | -14K -2.85% | 484,060 0.79% of shares | low |
| Jun 9, 2026 | Pierce Glenn Director | Grant | Stock Option (Right to Buy) | — | +30K | 30,000 0.05% of shares | low |
| Jun 9, 2026 | Geraghty James a Director | Grant | Stock Option (Right to Buy) | — | +30K | 30,000 0.05% of shares | low |
| Jun 9, 2026 | Scangos George a Director | Grant | Stock Option (Right to Buy) | — | +30K | 30,000 0.05% of shares | low |
| Feb 6, 2026 | Jorgensen Nathan D. Executive | Grant | Stock Option (Right to Buy) | — | +151K | 150,500 0.24% of shares | low |
| Feb 6, 2026 | Ferguson Toby Executive | Grant | Stock Option (Right to Buy) | — | +210K | 210,000 0.34% of shares | low |
| Feb 6, 2026 | Carter Todd Alfred Executive | Grant | Stock Option (Right to Buy) | — | +154K | 154,000 0.25% of shares | low |
| Feb 6, 2026 | Swartz Robin Executive | Grant | Stock Option (Right to Buy) | — | +210K | 210,000 0.34% of shares | low |
| Feb 6, 2026 | Sandrock Alfred CEO | Grant | Stock Option (Right to Buy) | — | +403K | 402,500 0.65% of shares | low |
| Jan 6, 2026 | Shiferman Gregory L. Executive | Grant | Stock Option (Right to Buy) | — | +100K | 100,000 0.16% of shares | low |